“MENLO PARK, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) — Geron Corporation (GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).
‘The start of the Phase 3 portion of IMerge is a significant milestone for Geron and imetelstat,’ said John A. Scarlett, M.D., Chairman and Chief Executive Officer. ‘We are hopeful that the Phase 3 will confirm the encouraging results from the Phase 2 portion, and that imetelstat could become a much-needed treatment alternative for patients with lower risk MDS.’ ”
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2019 The Hygiology Post ®
Bytecoin (BCN) Address: 29bxUxr7wa8AzP8tvkAJqT8S8R5XTdBwHce9hwPhWx9oMRrsd5hxFsqR1uxBuKvSejTYqVXC6TSe241KoxVg1sF2SXZ6Z9H
Verge (XVG) Address: DCF3g6Zj6g3NspfNeMs6JsEgCsAVmVmkg4
MaidSafeCoin/Safecoin (MAID) Address: Rtd6RWvA1xLFhHKYCfvk5dt7UsstdFcbfK